Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis

Published:2022-07 Issue: Volume:63 Page:103891
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Knudsen Maria Højberg^ORCID,Lindberg Ulrich,Frederiksen Jette Lautrup,Vestergaard Mark Bitsch,Simonsen Helle Juhl,Varatharaj Aravinthan,Galea Ian,Blinkenberg Morten,Sellebjerg Finn,Larsson Henrik Bo Wiberg,Cramer Stig Præstekjær

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference35 articles.

1. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab;Baker;JAMA Neurol,2017

2. The density of tissues in and about the head;Barber;Acta Neurol. Scand.,1970

3. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial;Center;Lancet,2012

4. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial;Cohen;Lancet,2012

5. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes;Coles;Lancet Neurol,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies;The Lancet Neurology;2024-01

2. Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in Plasma;Stroke;2023-11

3. Arginine vasopressin hormone receptor antagonists in experimental autoimmune encephalomyelitis rodent models: A new approach for human multiple sclerosis treatment;Frontiers in Neuroscience;2023-03-14

4. Changes in hippocampal volume during a preceding 10-year period do not correlate with cognitive performance and hippocampal blood‒brain barrier permeability in cognitively normal late-middle-aged men;GeroScience;2022-12-19

5. Neutrophil Nanovesicle Protects against Experimental Autoimmune Encephalomyelitis through Enhancing Myelin Clearance by Microglia;ACS Nano;2022-10-26